Review
Immunology
Quan Tang, Xian Peng, Bo Xu, Xuedong Zhou, Jing Chen, Lei Cheng
Summary: This review highlights the importance and potential of bacteria-based immunotherapy in cancer treatment. Through modern technologies like genetic engineering, bacteria can be modified to enhance tumor-targeting properties, immune modulation effect, and safety. Successful applications of engineered bacteria in cancer immunotherapy and potential opportunities in different cancer types are discussed.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Flora Gouzerh, Jean-Marie Bessiere, Beata Ujvari, Frederic Thomas, Antoine M. Dujon, Laurent Dormont
Summary: Cancer, as the second leading cause of death worldwide, has garnered much attention in early detection research. VOCs have shown promise as potential biomarkers in detecting cancers, with numerous studies highlighting their value in this field.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
(2022)
Review
Oncology
Anwen Xiong, Jiali Wang, Caicun Zhou
Summary: Lung cancer is a significant cause of morbidity and mortality in China and globally, with non-small cell lung cancer (NSCLC) being the predominant type and immune checkpoint inhibitors (ICIs) revolutionizing its treatment. Despite challenges, ICIs have shown promising antitumor efficacy in NSCLC and hold potential for future first-line treatment.
FRONTIERS IN ONCOLOGY
(2021)
Review
Oncology
Niklas Sturm, Jasmin Selina Schuhbaur, Felix Huttner, Lukas Perkhofer, Thomas Jens Ettrich
Summary: Gallbladder cancer, the most common malignancy of the biliary tract, has been associated with various risk factors. Surgical resection and chemotherapy can improve the prognosis of patients. Targeted therapy based on molecular profiling is a promising approach for the treatment of gallbladder cancer.
Review
Oncology
Jorge Cortes, Fabian Lang
Summary: CML is driven by the BCR-ABL1 fusion protein, making the ATP binding site of ABL1 an optimal target for TKIs. Despite improvements in prognosis, patients often fail treatment and require new therapeutic options.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Immunology
Lili Mao, Zhonghui Qi, Li Zhang, Jun Guo, Lu Si
Summary: Acral and mucosal melanomas are rare in Caucasians but predominant in Asians, displaying aggressive phenotypes and similar genetic landscapes. Current therapies show limited benefit for these subtypes, and mechanisms contributing to disparities remain unclear. Early diagnosis and effective interventions for these melanoma subtypes are crucial.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Pharmacology & Pharmacy
Xiao-Yuan Mao, Xi-Xi Yin, Qi-Wen Guan, Qin-Xuan Xia, Nan Yang, Hong-Hao Zhou, Zhao-Qian Liu, Wei-Lin Jin
Summary: Dietary nutrition plays a crucial role in brain function, aiding in the prevention and remediation of neurologic symptoms through mechanisms such as mitochondrial dysfunction, epigenetic modification, and neuroinflammation. Specific dietary interventions have shown promise in tackling neurological disorders, with metabolic control, epigenetic modification, neuroinflammation, and the gut-brain axis being highlighted as important factors for nutrient supply and therapeutic response. Additionally, reshaping the metabolism-epigenetics-immunity cycle through dietary nutrient intervention could provide a new blueprint for combatting neurological weaknesses.
PHARMACOLOGY & THERAPEUTICS
(2021)
Review
Immunology
Hirva Mamdani, Sandro Matosevic, Ahmed Bilal Khalid, Gregory Durm, Shadia I. Jalal
Summary: Lung cancer treatment has undergone major changes with the development of targeted therapies and immunotherapy. However, predicting response and overcoming resistance to immune checkpoint inhibitors remains challenging, necessitating the discovery of new predictive biomarkers. Additionally, exploring additional targets is important for maximizing the benefits of immunotherapy in lung cancer treatment.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Murali Ragothaman, So Young Yoo
Summary: Bacteriophages have emerged as versatile tools in bioengineering, with enormous potential in tissue engineering, vaccine development, and immunotherapy. They can be harnessed for the development of novel DNA vaccines and antigen display systems, providing a highly organized and repetitive presentation of antigens to immune cells. Bacteriophages also have potential in targeting specific molecular determinants of cancer cells.
Review
Biochemistry & Molecular Biology
Cynthia Mark, Jin Sun Lee, Xiaojiang Cui, Yuan Yuan
Summary: Antibody drug conjugates (ADCs) combine monoclonal antibodies with cytotoxic drugs for selective delivery to cancer cells, optimizing treatment effectiveness. ADC research has significantly impacted breast cancer management, providing valuable options. However, important questions remain, such as drug sequencing and overcoming resistance mechanisms.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Yiren Yang, Pengyu Liu, Mingyang Zhou, Linzhou Yin, Miao Wang, Ting Liu, Xiaowen Jiang, Huiyuan Gao
Summary: This review focuses on the current status and strategies of small molecule drugs for colorectal cancer (CRC) therapy. Despite the challenges posed by CRC's genetic susceptibility and molecular heterogeneity, new approaches such as dual/multiple-target drugs, drug repurposing, and combination therapies provide insights for improving CRC treatment in the future.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2024)
Article
Gastroenterology & Hepatology
Wei-Xin Cheng, Yue Ren, Miao-Miao Lu, Ling-Ling Xu, Jian-Guo Gao, Dong Chen, Farhin Shaheed Kalyani, Zi-Yan Lv, Chun-Xiao Chen, Feng Ji, He-Ning Lin, Xi Jin
Summary: S-palmitoylation is a common post-translational modification with potential implications for Crohn's disease. The pathophysiological mechanisms of CD are not fully understood, but genetic susceptibility, environmental factors, and altered gut microbiota are recognized risk factors. There is a growing global health issue related to bowel damage and disabilities caused by CD.
WORLD JOURNAL OF GASTROENTEROLOGY
(2021)
Review
Oncology
Arnold Lee
Summary: Niraparib is an oral medication used for the treatment of chemotherapy-responsive advanced ovarian cancer, regardless of the patient's DNA repair mechanisms. The main safety concern is abnormal blood counts. Personalized lower dosages may help reduce adverse drug reactions.
Review
Pathology
Lulu Sun, Ariel Wu, Gregory R. Bean, Ian S. Hagemann, Chieh-Yu Lin
Summary: This article provides an overview of the currently available molecular assays for breast cancer, discussing their prognostic, predictive, and therapeutic value. It also covers the detection methods for PIK3CA mutations, NTRK fusions, immune checkpoint inhibitors, as well as the potential utility of next-generation sequencing panels and circulating tumor DNA assays.
JOURNAL OF MOLECULAR DIAGNOSTICS
(2021)
Review
Oncology
Yiqun Zhang, Shijie Lan, Di Wu
Summary: Melanoma, especially acral melanoma (AM), poses significant challenges in terms of treatment and survival rates. AM is more common in people of color and has limited response to current therapies. Understanding the molecular and immune landscape of AM is crucial for improving treatment approaches.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Article
Oncology
Diego Salas-Benito, Enrique Conde, Ibon Tamayo-Uria, Uxua Mancheno, Edurne Elizalde, David Garcia-Ros, Jose M. Aramendia, Juan C. Muruzabal, Julia Alcaide, Francisco Guillen-Grima, Jose A. Minguez, Jose Amores-Tirado, Antonio Gonzalez-Martin, Pablo Sarobe, Juan J. Lasarte, Mariano Ponz-Sarvise, Carlos E. De Andrea, Sandra Hervas-Stubbs
Summary: In patients with ovarian cancer, PD-1 markers can be used to select tumour-infiltrating lymphocytes and identify predictive factors for tumour-reactive TILs, ultimately enhancing the effectiveness of adoptive immunotherapy. Our study found that tumor-specific CD8 TILs in ovarian cancer patients primarily come from the PD-1(+) cell population, and specific factors such as high TIL density, presence of CD137(+) cells, and location in the tumor epithelium, as well as a baseline T-cell-inflamed genetic signature and/or high TMB, can predict which patients are likely to generate tumor-reactive TIL products from PD-1(+) TILs.
BRITISH JOURNAL OF CANCER
(2021)
Meeting Abstract
Oncology
D. Chase, J. Perhanidis, D. Gupta, L. Kalilani, S. Lechpammer, T. Woodward, A. Gonzalez-Martin
ANNALS OF ONCOLOGY
(2021)
Meeting Abstract
Oncology
Erika P. Hamilton, Camille Catherine Jackson, Ramez Nassef Eskander, Floor Jenniskens Backes, Vicky Makker, Fernanda Musa, Alexander Olawaiye, Jill Alldredge, Bhavana Pothuri, Angeles Alvarez Secord, Nicole Concin, Antonio Gonzalez Martin, Jowell Go, Kenton Wride, Denise M. Lepley, Teresa Cameron, Manish R. Patel
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Meeting Abstract
Oncology
Jose Alejandro Perez-Fidalgo, Alfonso Cortes Salgado, Yolanda Garcia, Maria Iglesias, Uriel Bohn Sarmiento, Elisa Calvo Garcia, Luis Manso Sanchez, Ana Santaballa, Ana Oaknin, Andres Redondo, Maria Jesus Rubio, Antonio Gonzalez-Martin
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
A. Poveda, S. Lheureux, N. Colombo, D. Cibula, K. Lindemann, J. Weberpals, M. Bjurberg, A. Oaknin, M. Sikorska, A. Gonzalez-Martin, R. Madry, M. J. Rubio Perez, J. Ledermann, R. Davidson, C. Blakeley, J. Bennett, A. Barnicle, E. Skof
Summary: The OPINION trial investigated the efficacy of olaparib maintenance therapy in patients without deleterious mutations. The results showed clinical benefit in all subgroups.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
Philipp Harter, Marie Ange Mouret-Reynier, Sandro Pignata, Claire Cropet, Antonio Gonzalez-Martin, Gerhard Bogner, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Trine Jakobi Nottrup, Anne Floquet, Ahmed El-Balat, Giovanni Scambia, Eva Maria Guerra Alia, Michel Fabbro, Barbara Schmalfeldt, Anne-Claire Hardy-Bessard, Ingo Runnebaum, Eric Pujade-Lauraine, Isabelle Ray-Coquard
Summary: In the PAOLA-1 trial, maintenance olaparib plus bevacizumab provided a substantial PFS benefit in both higher-risk and lower-risk patients compared to bevacizumab alone. In the HRD-positive subgroup, olaparib plus bevacizumab showed significant PFS improvement in lower-risk patients.
GYNECOLOGIC ONCOLOGY
(2022)
Article
Oncology
I Vergote, A. Gonzalez-Martin, I Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M. R. Mirza, B. Brasiuniene, R. Madry, J. D. Brenton, M. G. E. M. Ausems, R. Buettner, D. Lambrechts
Summary: This study aimed to establish a European-wide consensus on genetic testing and clinical management for patients with newly diagnosed advanced ovarian cancer, as well as biomarkers for predicting the effectiveness of PARPi in first-line treatment. The consensus recommendations, based on input from experts across Europe, provide clear guidance on BRCA and HRR deficiency testing for these patients.
ANNALS OF ONCOLOGY
(2022)
Review
Oncology
Antonio Gonzalez-Martin, Ursula A. Matulonis, Jacob Korach, Mansoor R. Mirza, Kathleen N. Moore, Xiaohua Wu, Whitney York, Divya Gupta, Stanislav Lechpammer, Bradley J. Monk
Summary: This article reviewed the clinical data of niraparib monotherapy in BRCA-mutated epithelial ovarian cancer (OC) patients and compared the results with other poly(ADP-ribose) polymerase inhibitors (PARPis). Niraparib as first-line maintenance therapy reduced the risk of progression or death by 60% and by 73-78% in recurrent disease. Quality-of-life (QoL) was maintained throughout treatment. Adverse events were consistent with the known niraparib safety profile. Cumulative efficacy, safety, and QoL evidence demonstrate the positive benefit:risk ratio of niraparib maintenance monotherapy in BRCAm OC.
Article
Oncology
Antonio Gonzalez-Martin, Bhavana Pothuri, Ignace Vergote, Whitney Graybill, Domenica Lorusso, Colleen C. McCormick, Gilles Freyer, Floor Backes, Florian Heitz, Andres Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O'Cearbhaill, Izabela A. Malinowska, Luda Shtessel, Natalie Compton, Mansoor R. Mirza, Bradley J. Monk
Summary: This study reports the long-term efficacy and safety of the PRIMA/ENGOT-OV26/GOG-3012 trial. The results show that niraparib maintains clinically significant improvements in progression-free survival (PFS) in high-risk patients with newly diagnosed advanced ovarian cancer, regardless of HRD status. No new safety signals were identified.
EUROPEAN JOURNAL OF CANCER
(2023)
Review
Oncology
Bradley J. Monk, Antonio Gonzalez-Martin, Lynn Buckley, Ursula A. Matulonis, B. J. Rimel, Xiaohua Wu, Kathleen N. Moore, Mansoor R. Mirza
Summary: Niraparib, a PARP inhibitor, has shown significant improvement in progression-free survival for advanced epithelial ovarian cancer patients regardless of biomarker status. This review focuses on managing the adverse events associated with niraparib to maintain its efficacy and improve patients’ quality of life. Hematologic events, such as thrombocytopenia, anemia, and neutropenia, were the most commonly reported adverse events, while gastrointestinal events were generally low grade. Clinical strategies including cognitive behavioral therapy and pharmacologic agents are summarized for managing these events. Personalized starting dose of niraparib based on body weight and platelet count demonstrated improved safety profile. Long term safety data from NOVA trial confirmed that niraparib is well tolerated with appropriate and early dose modifications.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Review
Oncology
Ainhoa Madariaga, Rodrigo Sanchez-Bayona, Fernanda G. Herrera, Pedro T. Ramirez, Antonio Gonzalez Martin
Summary: Drug development plays a crucial role in improving outcomes for patients with gynecologic cancers. Clinical trials should measure whether new interventions result in clinically relevant improvements compared to standard care, using reproducible and appropriate endpoints. Overall survival and quality of life are the gold standards for measuring the benefits of new therapeutic strategies. Alternative endpoints, such as progression-free survival, provide early insights into the effects of new drugs but their correlation with overall survival or quality of life in gynecologic malignancies is unclear. Additionally, time-to-event endpoints like progression-free survival two and time to second subsequent treatment are valuable for assessing disease control in the longer term.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Editorial Material
Oncology
Ainhoa Madariaga, Robert L. Coleman, Antonio Gonzalez Martin
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Eva-Maria Willing, Claudia Vollbrecht, Christine Voessing, Peggy Weist, Simon Schallenberg, Johanna M. Herbst, Stefanie Schatz, Balazs Jori, Guillaume Bataillon, Philipp Harter, Vanda Salutari, Antonio Gonzales Martin, Ignace Vergote, Nicoletta Colombo, Julia Roeper, Tobias Berg, Regina Berger, Bettina Kah, Trine Jakobi Noettrup, Markus Falk, Kathrin Arndt, Andreas Polten, Isabelle Ray-Coquard, Franziska Selzam, Judith Pirngruber, Stefanie Schmidt, Michael Hummel, Markus Tiemann, David Horst, Jalid Sehouli, Eric Pujade-Lauraine, Katharina Tiemann, Elena Ioana Braicu, Lukas C. Heukamp
Summary: Genomic instability (GI) caused by homologous repair deficiency (HRD) is a clinically relevant biomarker that can identify patients with high-grade serous ovarian cancer who may benefit from PARP inhibitors and help annotate mutations in homologous repair pathway genes. A custom Agilent XT HS2 hybrid capture NGS assay was developed and validated to analyze HR pathway, BRCA1/2 alterations, and GI-Score (GIS) status in one tumor sample. The assay showed comparable results to the Myriad MyChoice assay in terms of progression-free survival (PFS) and overall survival (OS) in HRD-positive patients. The NOGGO GIS v1 assay demonstrated robustness and clinical utility. The establishment of a robust molecular diagnostic assay for driver mutations and GI in ovarian cancer is important for the worldwide approval of combination maintenance therapy in advanced disease.
Article
Oncology
Andres Redondo, Pilar Barretina, Alejandro Perez-Fidalgo, Maria Jesus Rubio, Antonio Gonzalez-Martin
Summary: The objective of this study was to reach a consensus on the management of controversial issues in advanced ovarian cancer. Through the use of nominal group and Delphi techniques, the study successfully achieved consensus on some key issues. The results of this study are significant for addressing controversial issues in the management of advanced ovarian cancer.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Meeting Abstract
Oncology
Ashish Banerjee, Antonio Gonzalez-Martin, Ursula Matulonis, Jacob Korach, Mansoor R. Mirza, Kathleen Moore, Divya Gupta, Stanislav Lechpammer, Bradley J. Monk
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2021)